1. Volume 24, Issue 4, Pages 291-295 (December 2017)
Two year follow-up of Crohn’s patients substituted to certolizumab anti-TNFa therapy: SAVANT 2 
Andrew Motlis, Moheb Boktor, Paul Jordan, Urska Cvek, Marjan Trutschl, J. Steven Alexander 
Pathophysiology 
Volume 24, Issue 4, Pages (December 2017)
DOI: /j.pathophys
Copyright © 2017 Elsevier B.V. Terms and Conditions

2. Fig. 1
Study design. Illustration showing that full induction was required for inclusion. Patients who were lost to follow up were not included in the failure group.
Pathophysiology  , DOI: ( /j.pathophys )
Copyright © 2017 Elsevier B.V. Terms and Conditions

3. Fig. 2
Graph illustrating the cumulative proportion of patients who lost maintained and lost responsiveness over the 12 and 24 month phases of the SAVANT 1 and SAVANT 2 study periods.
Pathophysiology  , DOI: ( /j.pathophys )
Copyright © 2017 Elsevier B.V. Terms and Conditions